Zacks: Analysts Expect TG Therapeutics, Inc. (NASDAQ:TGTX) Will Announce Earnings of -$0.49 Per Share

Equities research analysts expect that TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating) will announce earnings of ($0.49) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for TG Therapeutics’ earnings, with estimates ranging from ($0.67) to ($0.38). TG Therapeutics posted earnings of ($0.59) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 16.9%. The firm is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that TG Therapeutics will report full-year earnings of ($2.10) per share for the current year, with EPS estimates ranging from ($3.60) to ($1.20). For the next year, analysts anticipate that the firm will post earnings of ($1.25) per share, with EPS estimates ranging from ($2.23) to ($0.39). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow TG Therapeutics.

TG Therapeutics (NASDAQ:TGTXGet Rating) last released its quarterly earnings data on Tuesday, March 1st. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.08). The firm had revenue of $2.32 million for the quarter, compared to analyst estimates of $9.90 million. TG Therapeutics had a negative net margin of 4,126.45% and a negative return on equity of 118.49%. During the same period in the previous year, the business posted ($0.71) EPS.

A number of research firms recently issued reports on TGTX. Cantor Fitzgerald reissued an “overweight” rating on shares of TG Therapeutics in a research report on Monday, May 9th. HC Wainwright cut their target price on TG Therapeutics from $68.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, April 18th. B. Riley cut their target price on TG Therapeutics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, April 19th. Zacks Investment Research upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 26th. Finally, Bank of America assumed coverage on TG Therapeutics in a report on Friday, May 20th. They set an “underperform” rating on the stock. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $22.75.

Several institutional investors have recently bought and sold shares of the company. State Street Corp increased its stake in TG Therapeutics by 65.3% during the first quarter. State Street Corp now owns 9,628,584 shares of the biopharmaceutical company’s stock valued at $91,568,000 after acquiring an additional 3,804,406 shares during the period. Maverick Capital Ltd. increased its stake in TG Therapeutics by 83.1% during the fourth quarter. Maverick Capital Ltd. now owns 6,034,875 shares of the biopharmaceutical company’s stock valued at $114,663,000 after acquiring an additional 2,738,424 shares during the period. Norges Bank bought a new position in TG Therapeutics during the fourth quarter valued at about $19,436,000. Federated Hermes Inc. bought a new position in TG Therapeutics during the first quarter valued at about $7,442,000. Finally, RA Capital Management L.P. increased its stake in TG Therapeutics by 22.6% during the third quarter. RA Capital Management L.P. now owns 4,098,332 shares of the biopharmaceutical company’s stock valued at $136,392,000 after acquiring an additional 755,589 shares during the period. Institutional investors and hedge funds own 70.52% of the company’s stock.

TGTX traded up $0.08 during trading on Thursday, reaching $5.07. 120,379 shares of the stock traded hands, compared to its average volume of 2,641,502. The stock has a market cap of $732.29 million, a price-to-earnings ratio of -2.07 and a beta of 2.25. TG Therapeutics has a fifty-two week low of $4.73 and a fifty-two week high of $41.00. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.43 and a quick ratio of 4.43. The stock’s 50-day simple moving average is $8.05 and its two-hundred day simple moving average is $13.26.

About TG Therapeutics (Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

See Also

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Want More Great Investing Ideas?

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.